The meeting supported our view that Luna will become a must-have
technology in wound care.
Our research indicates that the company is seeing strong placement demand for its other
products as well. The company suggested that it would finish 2014 with over 100 sales
representatives, well above the prior target of 70.
Enthusiasm for Luna by podium presenters (many
of whom are users) was remarkably high. The consensus was that Luna was going to be a
mainstay in domestic wound care centers nationwide over time.
Interest and early traction in Luna driven by clinical benefits, reimbursement and
the potential draw for new patients
I can't help with the reports, but there are several short videos under wound care at the Novadaq
site that are quite compelling. Of interest are the multiple uses of the dye in before and after shots.
Analyst reports are generally available thugh websties (usually paid or client) or third party software, Bloomberg, FactSet, Reuters....the above snipits were from (William Blair & Company, L.L.C. & Piper Jaffray)
I checked out the conference web site. Had a picture of the new LUNA in the Novadaq exhibit but no verbal or written mention of the presentation. I could not tell from the web picture whether the presentation was well attended or not. From the pictures of other exhibits the LUNA seemed to be the one with the most to draw the conference goers attention. It would have been nice to have a video of the exhibits presenters on the NVDQ web site.